CSPG4 and melanoma: Similarly, CSPG4 expression was also shown to confer resistance of melanoma cells to TNFα, doxorubicin and cisplatin treatment, most likely through activation of α3β1 integrin/PI3K signalling, which promotes cell survival [54].